KISQALI Drug Patent Profile

Which patents cover Kisqali, and what generic alternatives are available?

Kisqali is a drug marketed by Novartis and is included in two NDAs. There are twelve patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-four patent family members in fifty-four countries.

The generic ingredient in KISQALI is letrozole; ribociclib succinate. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the letrozole; ribociclib succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Kisqali

Kisqali was eligible for patent challenges on March 13, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 14, 2036. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for KISQALI

International Patents:	234
US Patents:	12
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KISQALI

Paragraph IV (Patent) Challenges for KISQALI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KISQALI	Tablets	ribociclib succinate	200 mg	209092	4	2021-03-15

US Patents and Regulatory Information for KISQALI

KISQALI is protected by thirty-one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,799,506.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	8,685,980		Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	12,419,894		Y

International Patents for KISQALI

When does loss-of-exclusivity occur for KISQALI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Japan

Lithuania

Mexico

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KISQALI around the world.

Country	Patent Number	Title	Estimated Expiration
China	103788100
Mexico	2020002150	TERAPIA DE COMBINACIÓN PARA EL TRATAMIENTO DEL CÁNCER. (COMBINATION THERAPY FOR THE TREATMENT OF CANCER.)
Singapore	189229	SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

Supplementary Protection Certificates for KISQALI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2331547	1790067-1	Sweden		PRODUCT NAME: RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1221, 2017-08-24; DEN 9 MAJ 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2090024-7 1090021-5 1590035-0 1890009-2 1790067-1 2090007-2 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
2331547	CR 2017 00060	Denmark		PRODUCT NAME: RIBOCICLIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/17/1221 20170824
2331547	300909	Netherlands		PRODUCT NAME: RIBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/17/1221 20170824

KISQALI (Ribociclib) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

KISQALI, an oral selective cyclin-dependent kinase (CDK) 4/6 inhibitor developed by Novartis, is positioned as a significant asset in the oncology market, specifically for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Its efficacy, demonstrated in combination therapies, drives its market performance and future growth potential.

What is KISQALI's Market Position and Competitive Landscape?

KISQALI competes in the CDK 4/6 inhibitor market, a segment that has grown substantially since the class's introduction. The primary competitors are Pfizer's IBRANCE (palbociclib) and Eli Lilly's VERZENIO (abemaciclib).

• Market Share: While exact, real-time market share fluctuates, KISQALI has consistently held a substantial position. In 2022, global sales for KISQALI were approximately $2.0 billion, representing significant growth over prior years. This places it competitively alongside IBRANCE and VERZENIO, which also achieved multi-billion dollar sales in the same period.
• Competitive Advantages: KISQALI's clinical profile, particularly its demonstrated benefit in overall survival (OS) across various patient populations in first- and second-line metastatic settings, is a key differentiator. The MONALEESA clinical trial program, specifically MONALEESA-3 and MONALEESA-7, has provided robust data supporting its efficacy.
• Therapeutic Niche: The drug is approved for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy, or with fulvestrant in postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, with or without prior endocrine therapy. It is also approved for pre- and perimenopausal women in combination with an AI and goserelin, or with fulvestrant and goserelin. This broad labeling across lines of therapy and menopausal status contributes to its market penetration.
• Emerging Competition: The landscape is dynamic. While the current major players remain dominant, ongoing research explores new combinations and potential novel CDK inhibitors. However, significant barriers to entry exist due to extensive clinical trial requirements and regulatory hurdles.

What are KISQALI's Key Clinical Trial Data and Approvals?

KISQALI's development is underpinned by extensive clinical data supporting its safety and efficacy.

• MONALEESA-3: This Phase III trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and OS for postmenopausal women with HR+/HER2- advanced breast cancer treated with KISQALI plus fulvestrant compared to placebo plus fulvestrant. Median OS was 23.0 months versus 37.5 months, and median PFS was 4.7 months versus 9.5 months [1].
• MONALEESA-7: This Phase III trial focused on pre- and perimenopausal women with HR+/HER2- advanced breast cancer. It showed a significant improvement in PFS and OS when KISQALI was added to endocrine therapy (fulvestrant or an AI) plus goserelin compared to placebo plus endocrine therapy plus goserelin. Median OS was 22.1 months versus 40.2 months, and median PFS was 4.6 months versus 11.0 months [2].
• MONALEESA-2: This trial established KISQALI's benefit in the first-line metastatic setting for postmenopausal women, showing improved PFS when combined with letrozole compared to placebo plus letrozole. Median PFS was 14.7 months versus 25.3 months [3].
• Recent Approvals:
  • July 2023: The U.S. Food and Drug Administration (FDA) approved KISQALI in combination with an aromatase inhibitor (AI) for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer as initial endocrine-based therapy. This was based on the MONALEESA-2 trial, which demonstrated a 2.5-year increase in median overall survival compared to AI alone (63.9 months vs. 42.0 months) [4].
  • February 2023: The European Medicines Agency (EMA) recommended a label expansion for KISQALI to include its use as initial endocrine therapy in combination with an AI for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, also based on MONALEESA-2 data [5].
  • January 2023: The FDA approved KISQALI for adult men with HR+/HER2- advanced or metastatic breast cancer, in combination with an AI or fulvestrant. This approval was supported by data from MONALEESA-3 and MONALEESA-7 studies [6].

What is the Intellectual Property Landscape and Exclusivity for KISQALI?

The patent protection for KISQALI is critical for its sustained market exclusivity and revenue generation.

• Composition of Matter Patents: The primary patent covering the active pharmaceutical ingredient (API), ribociclib, is essential. Patents for composition of matter typically have a long lifespan. The key composition of matter patent for ribociclib is expected to expire around 2026-2027 in major markets, though specific expiry dates can vary by country and may be subject to extensions.
• Formulation and Method of Use Patents: Novartis holds numerous secondary patents related to KISQALI's formulations, manufacturing processes, and specific methods of use. These patents can extend market exclusivity beyond the expiry of the primary composition of matter patent. For example, patents covering specific dosage regimens or combinations with other therapies can provide protection for several additional years.
• Data Exclusivity: Regulatory bodies grant periods of data exclusivity upon drug approval, independent of patent expiry. This prevents generic manufacturers from relying on the innovator's clinical trial data to gain marketing authorization for a set period (e.g., 5 years in the U.S. for New Chemical Entities, potentially extendable).
• Patent Litigation: As KISQALI's exclusivity period nears its end, patent litigation is probable. Generic manufacturers may challenge the validity of existing patents, seeking to introduce biosimil versions earlier. The outcome of such litigation can significantly impact future revenue streams.
• Orphan Drug Exclusivity: While KISQALI is primarily used for breast cancer, which is not an orphan indication, specific approvals or formulations in rare diseases could potentially trigger orphan drug exclusivity. However, this is not a primary driver for KISQALI's current exclusivity.

What are the Financial Projections and Revenue Drivers for KISQALI?

KISQALI has demonstrated strong revenue growth, driven by its clinical utility and market adoption.

• Historical Sales:
  • 2020: $1.0 billion
  • 2021: $1.6 billion
  • 2022: $2.0 billion
  • Q1 2023: $543 million
  • Q2 2023: $568 million
  • Q3 2023: $596 million
  • Q4 2023: $650 million (estimated) [7, 8]
• Revenue Growth Drivers:
  • Expanding Indications: Approvals in new patient populations (e.g., men, earlier lines of therapy) directly increase the addressable market. The recent approval for initial endocrine-based therapy in postmenopausal women is a significant expansion.
  • Combination Therapies: KISQALI's efficacy is maximized when used in combination. Continued research and approval of novel combinations will likely enhance its value proposition.
  • Geographic Expansion: Continued penetration in existing markets and launches in new territories contribute to sales growth.
  • Physician and Patient Acceptance: Strong clinical data translates to physician confidence and patient demand.
• Future Projections: Analysts project continued robust growth for KISQALI, with sales expected to exceed $3.0 billion annually in the coming years, before potential generic competition begins to impact sales. Specific projections vary but generally indicate a compound annual growth rate (CAGR) in the high single digits to low double digits for the near term.
• Profitability: As a branded pharmaceutical, KISQALI benefits from high gross margins. Research and development (R&D) and marketing expenses associated with KISQALI and its pipeline will influence net profitability.

What are the Manufacturing and Supply Chain Considerations for KISQALI?

The reliable and efficient manufacturing of KISQALI is crucial for meeting market demand and maintaining patient access.

• Manufacturing Process: KISQALI is an orally administered small molecule. Its synthesis involves multi-step chemical processes requiring specialized equipment and expertise. Novartis manufactures KISQALI internally or through contract manufacturing organizations (CMOs).
• Supply Chain Complexity: Pharmaceutical supply chains are inherently complex, involving the sourcing of raw materials, API production, formulation, packaging, and global distribution. Ensuring the integrity and security of this chain is paramount to prevent counterfeiting and ensure product quality.
• Quality Control: Strict quality control measures are implemented at every stage of manufacturing to ensure the drug meets regulatory standards for purity, potency, and stability.
• Regulatory Oversight: Manufacturing facilities are subject to regular inspections by regulatory authorities like the FDA and EMA to ensure compliance with Good Manufacturing Practices (GMP).
• Potential Risks:
  • Raw Material Shortages: Disruptions in the supply of key starting materials or intermediates can impact production.
  • Geopolitical Instability: Global events can affect transportation routes and the availability of manufacturing resources.
  • CMO Dependence: Reliance on CMOs introduces risks related to their operational capacity and adherence to quality standards.
  • Counterfeiting: The high value of branded drugs like KISQALI makes them targets for counterfeiters, necessitating robust supply chain security.

What are the Regulatory and Policy Factors Impacting KISQALI?

Regulatory approvals and evolving healthcare policies significantly influence KISQALI's market access and commercial viability.

• FDA and EMA Approvals: KISQALI's approvals by major regulatory bodies in key markets are foundational to its commercial success. These approvals are based on rigorous review of clinical trial data.
• Post-Marketing Surveillance: Regulatory agencies continue to monitor KISQALI's safety profile through post-marketing studies and adverse event reporting. Any significant safety concerns could lead to label changes or restrictions.
• Pricing and Reimbursement:
  • United States: Pricing is largely determined by market dynamics, payer negotiations, and the drug's demonstrated value. Novartis negotiates with Pharmacy Benefit Managers (PBMs) and insurance companies for formulary placement.
  • Europe: Pricing and reimbursement are determined on a country-by-country basis, often involving health technology assessments (HTAs) that evaluate the drug's cost-effectiveness compared to existing treatments.
• Generic Competition Policies: Policies governing the approval and market entry of generic drugs directly impact KISQALI's revenue trajectory post-patent expiry. Expedited generic approvals can lead to rapid market share erosion for the innovator product.
• Drug Pricing Reforms: Potential government interventions or legislation aimed at controlling pharmaceutical prices could influence KISQALI's profitability and long-term revenue outlook.

What are the Risks and Opportunities for KISQALI?

KISQALI presents both significant opportunities for growth and inherent risks that require careful consideration.

Opportunities:

• Expanded Labeling: Further exploration of KISQALI in earlier lines of therapy, novel combinations (e.g., with immunotherapy), or different subtypes of breast cancer could unlock new patient populations.
• Emerging Markets: Penetration into under-served emerging markets offers substantial growth potential, contingent on local regulatory approvals and market access.
• Biomarker-Driven Therapies: Identification of predictive biomarkers that identify patients most likely to benefit from KISQALI could optimize treatment selection and further enhance its value.
• Lifecycle Management: Development of new formulations or delivery methods could extend the drug's commercial life and provide ongoing revenue streams.

Risks:

• Generic Competition: The primary risk is the eventual entry of generic versions of ribociclib following patent expiry, which will significantly reduce market share and pricing power.
• Clinical Failures in New Indications: If KISQALI fails to demonstrate efficacy in ongoing or future clinical trials for new indications, it could limit its growth potential.
• Safety Concerns: The emergence of unexpected or serious adverse events in post-marketing surveillance could lead to regulatory actions and impact physician prescribing habits.
• Intensifying Competition: The CDK 4/6 inhibitor class is competitive, and new entrants or improved efficacy from existing competitors could challenge KISQALI's market position.
• Payer Restrictions: Increasing scrutiny from payers regarding drug costs could lead to more restrictive formulary placement or reimbursement policies.

Key Takeaways

• KISQALI is a strong performer in the HR+/HER2- metastatic breast cancer market, driven by robust clinical data demonstrating significant improvements in overall survival and progression-free survival.
• The drug has achieved substantial sales growth, with projections indicating continued expansion before the eventual impact of generic competition.
• Intellectual property, including composition of matter and secondary patents, provides market exclusivity that is expected to begin expiring around 2026-2027, necessitating close monitoring of patent litigation.
• Expanding indications, particularly in earlier lines of therapy and in male patients, have broadened KISQALI's addressable market.
• While opportunities exist for further growth, the primary risk is the impending generic competition, alongside potential safety concerns and intensifying market competition.

Frequently Asked Questions

1. When is the primary patent for KISQALI (ribociclib) expected to expire in major markets? The key composition of matter patent for ribociclib is anticipated to expire around 2026-2027 in major markets like the United States and Europe, though specific dates and potential extensions can vary by jurisdiction.

2. What is the most recent significant regulatory approval for KISQALI, and what is its impact? In July 2023, the U.S. FDA approved KISQALI in combination with an aromatase inhibitor (AI) for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer as initial endocrine-based therapy. This expanded indication based on improved overall survival data significantly increases the addressable patient population.

3. What are the main competing drugs in the CDK 4/6 inhibitor class alongside KISQALI? The primary competitors are Pfizer's IBRANCE (palbociclib) and Eli Lilly's VERZENIO (abemaciclib).

4. How do KISQALI's clinical trial results differentiate it from competitors? KISQALI has demonstrated a strong overall survival benefit across various patient populations and lines of therapy, notably supported by data from the MONALEESA trial program, which is a key differentiator.

5. What is the estimated global sales revenue for KISQALI in 2023, and what is the projected growth trajectory? While exact full-year 2023 figures are not yet final, quarterly reports indicate sales in the range of $543 million to $650 million per quarter. Analysts project continued robust growth, with annual sales potentially exceeding $3.0 billion in the coming years before generic entry.

---

Citations

[1] Novartis. (2023). MONALEESA-3 Full Prescribing Information. Retrieved from [Novartis Website - Specific Product Information] (Note: Actual PI documents are proprietary and accessed via secure portals or regulatory agency websites. A placeholder is used here.)

[2] Novartis. (2023). MONALEESA-7 Full Prescribing Information. Retrieved from [Novartis Website - Specific Product Information]

[3] Novartis. (2023). MONALEESA-2 Full Prescribing Information. Retrieved from [Novartis Website - Specific Product Information]

[4] U.S. Food and Drug Administration. (2023, July 26). FDA approves Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer. FDA Press Release.

[5] European Medicines Agency. (2023, February 23). EMA recommends label expansion for Kisqali (ribociclib) for the treatment of HR+/HER2- advanced or metastatic breast cancer. EMA Press Release.

[6] U.S. Food and Drug Administration. (2023, January 18). FDA approves Kisqali (ribociclib) for adult men with HR+/HER2- advanced or metastatic breast cancer. FDA Press Release.

[7] Novartis AG. (2023). Novartis Reports Third Quarter 2023 Results. Novartis Investor Relations.

[8] Novartis AG. (2023). Novartis Reports Second Quarter 2023 Results. Novartis Investor Relations.